Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients

Abstract Decision to undergo risk-reducing mastectomy (RRM) needs to consider several factors, including patient’s preference, surgeon’s preference, family history, and genetic predisposition. The aim of this study was to examine whether preoperative diagnosis of BRCA1/2 mutation status could influe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jinsun Woo, Geumhee Gwak, Inseok Park, Byung Noe Bae, Se Kyung Lee, Byung Joo Chae, Jonghan Yu, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Jai Min Ryu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/20e980d3160148c4a9c2384f27b998e9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:20e980d3160148c4a9c2384f27b998e9
record_format	dspace
spelling	oai:doaj.org-article:20e980d3160148c4a9c2384f27b998e92021-12-02T16:17:22ZPreoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients10.1038/s41598-021-94195-42045-2322https://doaj.org/article/20e980d3160148c4a9c2384f27b998e92021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-94195-4https://doaj.org/toc/2045-2322Abstract Decision to undergo risk-reducing mastectomy (RRM) needs to consider several factors, including patient’s preference, surgeon’s preference, family history, and genetic predisposition. The aim of this study was to examine whether preoperative diagnosis of BRCA1/2 mutation status could influence surgical decision-making in newly diagnosed breast cancer patients. We retrospectively reviewed ipsilateral breast cancer patients with BRCA1/2 mutation who underwent primary surgery between January 2008 and November 2019 at a single institution in Korea. Of 344 eligible patients, 140 (40.7%) patients were aware of their mutation status ‘prior to surgery’, while 204 (59.3%) did not. Contralateral RRM rate was significantly higher in the group with BRCA1/2 mutation status identified ‘prior to surgery’ compared to the group with mutation status identified ‘after surgery’ [45.0% (63/140) vs. 2.0% (4/204)] (p < 0.001). Reduced turnaround time of BRCA1/2 testing (p < 0.001) and the use of neoadjuvant chemotherapy (p < 0.001) were associated with BRCA1/2 mutation status identified prior to surgery. Although not statistically significant, higher incidence of developing contralateral breast cancer for BRCA1/2 mutation carriers who underwent ipsilateral surgery-only compared to those who underwent contralateral RRM was observed [12.1% (95% CI: 7.7–17.7%)] (p = 0.1618). Preoperative diagnosis of BRCA1/2 mutation could impact surgical decision-making for breast cancer patients to undergo risk-reducing surgery at the time of initial surgery.Jinsun WooGeumhee GwakInseok ParkByung Noe BaeSe Kyung LeeByung Joo ChaeJonghan YuJeong Eon LeeSeok Won KimSeok Jin NamJai Min RyuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jinsun Woo Geumhee Gwak Inseok Park Byung Noe Bae Se Kyung Lee Byung Joo Chae Jonghan Yu Jeong Eon Lee Seok Won Kim Seok Jin Nam Jai Min Ryu Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients
description	Abstract Decision to undergo risk-reducing mastectomy (RRM) needs to consider several factors, including patient’s preference, surgeon’s preference, family history, and genetic predisposition. The aim of this study was to examine whether preoperative diagnosis of BRCA1/2 mutation status could influence surgical decision-making in newly diagnosed breast cancer patients. We retrospectively reviewed ipsilateral breast cancer patients with BRCA1/2 mutation who underwent primary surgery between January 2008 and November 2019 at a single institution in Korea. Of 344 eligible patients, 140 (40.7%) patients were aware of their mutation status ‘prior to surgery’, while 204 (59.3%) did not. Contralateral RRM rate was significantly higher in the group with BRCA1/2 mutation status identified ‘prior to surgery’ compared to the group with mutation status identified ‘after surgery’ [45.0% (63/140) vs. 2.0% (4/204)] (p < 0.001). Reduced turnaround time of BRCA1/2 testing (p < 0.001) and the use of neoadjuvant chemotherapy (p < 0.001) were associated with BRCA1/2 mutation status identified prior to surgery. Although not statistically significant, higher incidence of developing contralateral breast cancer for BRCA1/2 mutation carriers who underwent ipsilateral surgery-only compared to those who underwent contralateral RRM was observed [12.1% (95% CI: 7.7–17.7%)] (p = 0.1618). Preoperative diagnosis of BRCA1/2 mutation could impact surgical decision-making for breast cancer patients to undergo risk-reducing surgery at the time of initial surgery.
format	article
author	Jinsun Woo Geumhee Gwak Inseok Park Byung Noe Bae Se Kyung Lee Byung Joo Chae Jonghan Yu Jeong Eon Lee Seok Won Kim Seok Jin Nam Jai Min Ryu
author_facet	Jinsun Woo Geumhee Gwak Inseok Park Byung Noe Bae Se Kyung Lee Byung Joo Chae Jonghan Yu Jeong Eon Lee Seok Won Kim Seok Jin Nam Jai Min Ryu
author_sort	Jinsun Woo
title	Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients
title_short	Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients
title_full	Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients
title_fullStr	Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients
title_full_unstemmed	Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients
title_sort	preoperative diagnosis of brca1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/20e980d3160148c4a9c2384f27b998e9
work_keys_str_mv	AT jinsunwoo preoperativediagnosisofbrca12mutationimpactsdecisionmakingforriskreducingmastectomyinbreastcancerpatients AT geumheegwak preoperativediagnosisofbrca12mutationimpactsdecisionmakingforriskreducingmastectomyinbreastcancerpatients AT inseokpark preoperativediagnosisofbrca12mutationimpactsdecisionmakingforriskreducingmastectomyinbreastcancerpatients AT byungnoebae preoperativediagnosisofbrca12mutationimpactsdecisionmakingforriskreducingmastectomyinbreastcancerpatients AT sekyunglee preoperativediagnosisofbrca12mutationimpactsdecisionmakingforriskreducingmastectomyinbreastcancerpatients AT byungjoochae preoperativediagnosisofbrca12mutationimpactsdecisionmakingforriskreducingmastectomyinbreastcancerpatients AT jonghanyu preoperativediagnosisofbrca12mutationimpactsdecisionmakingforriskreducingmastectomyinbreastcancerpatients AT jeongeonlee preoperativediagnosisofbrca12mutationimpactsdecisionmakingforriskreducingmastectomyinbreastcancerpatients AT seokwonkim preoperativediagnosisofbrca12mutationimpactsdecisionmakingforriskreducingmastectomyinbreastcancerpatients AT seokjinnam preoperativediagnosisofbrca12mutationimpactsdecisionmakingforriskreducingmastectomyinbreastcancerpatients AT jaiminryu preoperativediagnosisofbrca12mutationimpactsdecisionmakingforriskreducingmastectomyinbreastcancerpatients
_version_	1718384218849935360

Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients

Ejemplares similares